- Home
- QFIN vs SANA Comparison
QFIN vs SANA Comparison
Compare QFIN & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | QFIN | SANA |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 690.6M | 688.5M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | QFIN | SANA |
|---|---|---|
| Price | $5.62 | $2.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 9 |
| Target Price | ★ $14.59 | $8.43 |
| AVG Volume (30 Days) | 1.8M | ★ 2.8M |
| Earning Date | 11-17-2026 | 11-05-2026 |
| Dividend Yield | ★ 28.57% | N/A |
| EPS Growth | N/A | ★ 17.24 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.21 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.10 | $2.22 |
| 52 Week High | $23.79 | $5.49 |
Technical Indicators
Market Signals| Indicator | QFIN | SANA |
|---|---|---|
| Relative Strength Index (RSI) | 40.74 | 43.96 |
| Support Level | $5.10 | $2.22 |
| Resistance Level | $5.77 | $3.41 |
| Average True Range (ATR) | 0.29 | 0.17 |
| MACD | 0.13 | 0.03 |
| Stochastic Oscillator | 76.41 | 35.39 |
Price Performance
Historical ComparisonAbout QFIN Qifu Technology Inc.
Qfin Holdings Inc is engaged in matching individual borrowers with credit demand to a diversified pool of financial institutions with credit to supply through a financial technology platform. It has released large-scale financial credit multimodal benchmark, building a critical bridge between credit AI research and real-world applications.
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates comprises SC291, SC262, UP421, and others.